ストックスクリーナーアプリを入手
5.83
9.38%
0.50
アフターアワーズ：
5.83
前日終値:
$5.33
開ける：
$5.62
24時間の取引高:
10,800
Relative Volume:
0.63
時価総額：
$208.13M
収益：
$7.80M
当期純損益:
$-69.02M
株価収益率:
-2.8907
EPS:
-2.0168
ネットキャッシュフロー:
$-66.61M
1週間 パフォーマンス:
+0.20%
1か月 パフォーマンス:
+19.71%
6か月 パフォーマンス:
+54.23%
1年 パフォーマンス:
+34.33%
1日の値動き範囲:
$5.4454
$5.85
1週間の範囲:
$5.11
$5.85
52週間の値動き範囲:
$3.32
$12.70
Molecular Partners Ag Adr Stock (MOLN) Company Profile
MOLN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| MOLN | 5.83 | 208.13M | 7.80M | -69.02M | -66.61M | -2.0168 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-08-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | 開始されました | Cowen | Outperform |
| 2021-07-12 | 再開されました | SVB Leerink | Outperform |
すべてを表示
Molecular Partners Ag Adr (MOLN) 最新ニュース
Molecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M - TipRanks
Molecular Partners, Orano Med announce presentation of MP0712 data - TipRanks
Molecular Partners expands 212Pb co-development agreement with Orano Med - TipRanks
Molecular Partners shares gain on Leerink's outperform rating - Investing.com
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move ... - Yahoo News UK
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - GlobeNewswire Inc.
Molecular Partners' New Therapy Shows AML Treatment PromiseTipRanks.com - TipRanks
Molecular Partners Unveils Promising Cancer Therapy - TipRanks
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket By Benzinga - Investing.com UK
Molecular Partners Shares Rise on Positive Trial Data for MP0317 - MarketWatch
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19 - Yahoo Singapore News
Rigel Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com UK
US stock market gainers for the last week of April 2022 - Nairametrics
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com India
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOsiShares Biote - Benzinga
Molecular Partners (MLLCF) Stock Price, News & Analysis - MarketBeat
Market Data Center - Barron's
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Molecular Partners Ag Adr (MOLN) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):